MiNK Therapeutics (INKT) Misses Q2 EPS by 106c

MiNK Therapeutics (NASDAQ: INKT) reported Q2 EPS of ($1.06).

For earnings history and earnings-related data on MiNK Therapeutics (INKT) click here.

You May Also Be Interested In

• Oracle (ORCL) Reiterated at Market Outperform by Citizens on Positive Due Diligence Results
• JPMorgan Upgrades Lithium Americas Corp. (LAC:CN) (LAC) to Overweight
• Barnes & Noble Education (BNED) Tops Q1 EPS by 12c